8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Oct 3, 2024)

Filed October 3, 2024For Securities:ABBV

Summary

AbbVie Inc. (ABBV) has filed an 8-K report on October 3, 2024, to provide preliminary updates on its third-quarter 2024 financial performance, specifically regarding acquired in-process research and development (IPR&D) and milestones expenses. The company anticipates that these expenses will negatively impact both its GAAP and non-GAAP diluted earnings per share by approximately $0.04 on a pre-tax basis. This filing also revises AbbVie's full-year 2024 adjusted diluted earnings per share guidance to a range of $10.67 - $10.87, incorporating these newly accounted for third-quarter expenses. This disclosure is important for investors as it signals an unplanned increase in R&D-related expenses that affects profitability metrics. While AbbVie typically does not forecast these specific types of expenses due to their unpredictable nature, the company is providing updated guidance to reflect their inclusion. Investors should note that these are preliminary estimates and the final results for the third quarter are subject to the company's financial statement closing procedures.

Key Highlights

  • 1AbbVie anticipates $82 million in pre-tax acquired IPR&D and milestones expense for Q3 2024.
  • 2This expense is expected to reduce both GAAP and non-GAAP diluted EPS by $0.04.
  • 3Full-year 2024 adjusted diluted EPS guidance is revised to $10.67 - $10.87, including Q3 expenses.
  • 4Q3 2024 adjusted diluted EPS guidance is updated to $2.88 - $2.92, reflecting these expenses.
  • 5AbbVie does not typically forecast acquired IPR&D and milestones expenses due to inherent uncertainties.
  • 6The provided figures are preliminary estimates and are subject to final financial closing procedures.

Frequently Asked Questions

Acquired IPR&D and milestones expenses relate to costs incurred when AbbVie enters into collaborations, licensing agreements, or acquires other assets. These expenses are associated with research and development activities that have not yet reached regulatory approval.

AbbVie is filing this 8-K to provide investors with an early update on the financial impact of these specific expenses, which were not previously forecasted. This allows for a more informed view of the company's expected quarterly and full-year financial performance.

The full-year 2024 adjusted diluted EPS guidance has been updated to a range of $10.67 - $10.87 to incorporate the estimated Q3 acquired IPR&D and milestones expense. The Q3 guidance itself has also been revised to $2.88 - $2.92.

No, these are preliminary estimates. The report states that results for the quarter ended September 30, 2024, have not been finalized and are subject to the company's financial statement closing procedures. There is a possibility that the final results may differ from these estimates.